TrialCancer immunology, immunotherapy : CII2024

A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)

Manon Vounckx et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.